CXCL8 and renal cell carcinoma: Furthermore, single-cell RNA-sequencing demonstrated a difference in therapeutic response according to the source of IL-8; IL-8 was produced by myeloid and lymphoid cells in patients not responding to immune checkpoint inhibitors (ICI) but not in those treated with chemotherapy or anti-angiogenic agents and was significantly correlated with worse OS in patients affected by urothelial cancer and renal cell carcinomas [28].